DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for limb-girdle muscular dystrophy — screening already-approved drugs against its 43-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleLimb-girdle muscular dystrophy maps to a 43-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for limb-girdle muscular dystrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
spectrin repeat containing nuclear envelope protein 1 (SYNE1) — SYNE1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pgedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6R15 · 1.82 Å · ligand TRIETHYLENE GLYCOL (PGE). Experimental structure, not a prediction.
What the evidence adds up to
In a double-blind, crossover trial of 36 patients with various muscular dystrophies, six had sarcoglycan-deficient limb-girdle muscular dystrophy. After eight weeks of creatine monohydrate, there was mild but significant improvement in muscle strength and daily-life activities measured by Medical Research Council scales and the Neuromuscular Symptom Score. Creatine was well tolerated. The sample size for the limb-girdle subgroup was too small to draw separate conclusions.
No other drug trial results for limb-girdle muscular dystrophy were reported in these abstracts. A 2012 review noted that new therapeutic approaches had led to clinical trials in limb-girdle dystrophies, but gave no data. A 2025 update on dystrophinopathy — Duchenne and Becker muscular dystrophy — described FDA-approved treatments such as vamorolone, givinostat, and delandistrogene moxeparvovec, but these are not for limb-girdle muscular dystrophy. A 2023 chapter on drug repositioning for muscular dystrophies stated that MD has no cure and that effective treatments have yet to be developed, despite knowledge of the genetic origins.
What is still missing are dedicated, adequately powered trials for limb-girdle muscular dystrophy subtypes. The creatine study included only six such patients and did not report outcomes separately. No repurposed drug has shown efficacy in a controlled limb-girdle trial. Funding for subtype-specific trials, better patient stratification by genetic mutation, and trial designs that account for the slow progression of the disease remain absent.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurology · 2000 · 168 citations
Creatine monohydrate in muscular dystrophies: A double-blind, placebo-controlled clinical study
AbstractThe authors assessed the safety and efficacy of creatine monohydrate (Cr) in various types of muscular dystrophies in a double-blind, crossover trial. Thirty-six patients (12 patients with facioscapulohumeral dystrophy, 10 patients with Becker dystrophy, 8 patients with Duchenne dystrophy, and 6 patients with sarcoglycan-deficient limb girdle muscular dystrophy) were randomized to receive Cr or placebo for 8 weeks. There was mild but significant improvement in muscle strength and daily-life activities by Medical Research Council scales and the Neuromuscular Symptom Score. Cr was well tolerated throughout the study period.
Human Molecular Genetics · 2000 · 152 citations · open access
Animal models for muscular dystrophy: valuable tools for the development of therapies
AbstractSince the identification of dystrophin as the causative factor in Duchenne muscular dystrophy, an increasing amount of information on the molecular basis of muscular dystrophies has facilitated the division of these heterogeneous disorders into distinct groups. As more light is being shed on the genes and proteins involved in muscular dystrophy, diagnosis of patients has improved enormously. In addition to naturally occurring animal models, a number of genetically engineered murine models for muscular dystrophy have been generated. These animal models have provided valuable clues to the understanding of the pathogenesis of these disorders. Furthermore, as therapeutic approaches are being developed, mutant animals represent good models in which they can be tested. The present review focuses on the recent advancements of gene transfer-based strategies, with a special emphasis on animal models for Duchenne and limb-girdle muscular dystrophies.
AbstractThe muscular dystrophies are disorders of progressive muscular degeneration and weakness. As a group they display clinical heterogeneity that reflects the heterogeneity of molecular mechanisms responsible for them, and range from congenital to adulthood onset. Recent advances in the field include improved methods of diagnosis, continued identification of disease genes, and the development of a unified model of pathogenesis in facioscapulohumeral dystrophy. These advances are reflected in the development of new therapeutic approaches, some of which have already led to clinical trials in the dystrophinopathies and limb-girdle dystrophies.
The medical letter on drugs and therapeutics/The medical letter · 2024 · 3 citations
Givinostat (Duvyzat) for Duchenne Muscular Dystrophy
AbstractGivinostat (Duvyzat – Italfarmaco), an oral histone deacetylase inhibitor, has been approved by the FDA for treatment of patients ≥6 years old with Duchenne muscular dystrophy (DMD), regardless of the DMD-causing mutation. It is the first nonsteroidal drug to be approved for this indication. The oral corticosteroids deflazacort (Emflaza) and vamorolone (Agamree) are also approved for treatment of patients with all genetic variants of DMD.
Current Treatment Options in Neurology · 2025 · 1 citations · open access
Update on Treatment of Dystrophinopathy
AbstractAbstract Purpose of Review Dystrophinopathy is a spectrum of X-linked disorders caused by mutations in the DMD gene, leading to absent or decreased dystrophin protein. This group of conditions includes Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), as well as others such as DMD -associated dilated cardiomyopathy (DCM) and cramps with myoglobinuria. This review provides an overview of the clinical presentation, diagnostic approach, and management of dystrophinopathy, with an emphasis on recent therapeutic advances. Recent Findings Recent years have seen an acceleration in the development of promising gene-targeted approaches, such as gene transfer of microdystrophins and a new generation of exon-skipping RNA-based therapies. The recent US Food and Drug Administration (FDA) approval of treatments like vamorolone, givinostat, and delandistrogene moxeparvovec highlights the progress in the field. Other potential therapies are currently in clinical trials. Despite these advances, the backbone of treatment remains a comprehensive multidisciplinary approach, supported by treatments that have been established as standard of care. Newborn screening pilots can assist with early identification and intervention for males affected by dystrophinopathy. Summary Emerging therapies hold promise for altering the course of dystrophinopathy. Ongoing research will continue to refine genetic therapies and explore alternative therapeutic mechanisms. Ultimately, early diagnosis resulting in the integration of novel treatments with established multidisciplinary approaches offers the clearest path forward for improving outcomes in dystrophinopathy.
IntechOpen eBooks · 2023 · 0 citations · open access
The Potential Benefits of Drug-Repositioning in Muscular Dystrophies
AbstractMuscular dystrophies (MDs) are a complex group of rare neuromuscular disorders caused by genetic mutations that progressively weaken the muscles, resulting in an increasing level of disability. The underlying cause of these conditions consists of mutations in the genes in charge of a person’s muscle composition and functionality. MD has no cure, but medications and therapy can help control symptoms and slow the disease’s progression. Effective treatments have yet to be developed, despite the identification of the genetic origins and a thorough knowledge of the pathophysiological alterations that these illnesses induce. In this scenario, there is an urgent need for novel therapeutic options for these severe illnesses, and drug repositioning might be one feasible answer. In other words, drug repositioning/repurposing is an accelerated method of developing novel pharmaceuticals since the new indication is based on previously accessible safety, pharmacokinetic, and manufacturing data. This is particularly crucial for individuals with life-threatening illnesses such as MDs, who cannot wait for a conventional medication development cycle. This chapter aims to review the challenges and opportunities of drug-repositioning in a variety of MDs to establish novel treatment approaches for these incurable diseases.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
